Therapeutic Area: Oncology
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2020
Drug manufacturer TG Therapeutics, Inc., initiated a rolling application of an NDA for umbralisib seeking rapid FDA approval of the drug for the intended clinical use.